Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more
Immuneering Corp (IMRX) - Net Assets
Latest net assets as of September 2025: $227.98 Million USD
Based on the latest financial reports, Immuneering Corp (IMRX) has net assets worth $227.98 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($241.06 Million) and total liabilities ($13.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $227.98 Million |
| % of Total Assets | 94.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 15.3 |
Immuneering Corp - Net Assets Trend (2019–2024)
This chart illustrates how Immuneering Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immuneering Corp (2019–2024)
The table below shows the annual net assets of Immuneering Corp from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $41.39 Million | -54.31% |
| 2023-12-31 | $90.58 Million | -17.55% |
| 2022-12-31 | $109.85 Million | -29.57% |
| 2021-12-31 | $155.98 Million | +793.82% |
| 2020-12-31 | $-22.48 Million | -244.36% |
| 2019-12-31 | $-6.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immuneering Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21559744400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.05K | 0.08% |
| Other Components | $265.65 Million | 641.88% |
| Total Equity | $41.39 Million | 100.00% |
Immuneering Corp Competitors by Market Cap
The table below lists competitors of Immuneering Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kexin Development Co Ltd Shanxi
SHG:600234
|
$235.85 Million |
|
Pro Real Estate Investment Trust
PINK:PRVFF
|
$235.86 Million |
|
Saga plc
PINK:SGPLF
|
$235.89 Million |
|
EnQuest PLC
PINK:ENQUF
|
$235.91 Million |
|
Stewards Inc.
NASDAQ:SWRD
|
$235.72 Million |
|
Bintang Oto Global Tbk PT
JK:BOGA
|
$235.68 Million |
|
WITHSECURE CORP.
F:DTV0
|
$235.64 Million |
|
Zhengyuan Geomatics Group Co Ltd
SHG:688509
|
$235.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immuneering Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 90,576,183 to 41,386,226, a change of -49,189,957 (-54.3%).
- Net loss of 61,036,608 reduced equity.
- New share issuances of 4,237,397 increased equity.
- Other comprehensive income increased equity by 778.
- Other factors increased equity by 7,608,476.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.04 Million | -147.48% |
| Share Issuances | $4.24 Million | +10.24% |
| Other Comprehensive Income | $778.00 | +0.0% |
| Other Changes | $7.61 Million | +18.38% |
| Total Change | $- | -54.31% |
Book Value vs Market Value Analysis
This analysis compares Immuneering Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.48 | $4.78 | x |
| 2020-12-31 | $-1.66 | $4.78 | x |
| 2021-12-31 | $5.93 | $4.78 | x |
| 2022-12-31 | $4.16 | $4.78 | x |
| 2023-12-31 | $3.19 | $4.78 | x |
| 2024-12-31 | $1.38 | $4.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immuneering Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -147.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.27x
- Recent ROE (-147.48%) is below the historical average (-45.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -401.59% | 0.14x | 0.00x | $-7.06 Million |
| 2020 | 0.00% | -737.17% | 0.06x | 0.00x | $-14.79 Million |
| 2021 | -21.50% | -1612.33% | 0.01x | 1.07x | $-49.13 Million |
| 2022 | -45.98% | -15937.29% | 0.00x | 1.11x | $-61.50 Million |
| 2023 | -59.03% | -11752004.84% | 0.00x | 1.13x | $-62.53 Million |
| 2024 | -147.48% | 0.00% | 0.00x | 1.27x | $-65.18 Million |
Industry Comparison
This section compares Immuneering Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immuneering Corp (IMRX) | $227.98 Million | 0.00% | 0.06x | $235.75 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |